CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 194 enrolled
Drug / intervention
Rapid respiratory pathogen nucleic acid amplification testdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02957136
NCT02957136N/ACompleted

Randomized Clinical Trial of Multi-respiratory Pathogen Testing Versus Usual Care in Emergency Department (ED) Patients With Upper Respiratory Symptoms

University of California, Davis·interventional·Posted Nov 7, 2016·Updated May 19, 2021

In Brief

A clinical study evaluating Rapid respiratory pathogen nucleic acid amplification test for Respiratory Tract Infections and 2 related conditions. Completed, enrolled 194 participants across 1 site.

Detailed Summary

This is a randomized clinical trial to assess the effect of rapid, near point-of-care testing for multiple common respiratory viruses and bacteria on antibiotic and anti-influenza medication use in emergency department (ED) patients with symptoms of influenza-like illness (ILI) and/or upper respiratory infection (URI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedNov 7, 2016
Enrollment StartDec 8, 2016
Primary CompletionApr 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.7 years ago

Interventions

Rapid respiratory pathogen nucleic acid amplification testdevice

Patients randomized to the rapid respiratory pathogen nucleic acid amplification test (Film Array Respiratory Panel, BioFire Diagnostics), will receive usual physician-directed care plus results from a rapid diagnostic test for 20 common respiratory pathogens. Patients will have a nasopharyngeal swab sample collected and tested during the ED episode of care with results reported in the electronic medical record (EMR) within two hours of sample collection. ED physicians will receive education regarding the rapid respiratory pathogen test prior to commencing the study. During the study, ED physicians will be free to review and interpret the respiratory pathogen test results and make treatment decisions based on their individual clinical judgment without involvement of study personnel.